Eliud Irizarry Claudio
Neurology · Roanoke, VANPI 1508950122
Payments from drug & device makers
Across 170 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$249
- Biogen$219
- AstraZeneca$190
- Sanofi$185
- Lundbeck LLC$185
- Sunovion Pharmaceuticals Inc.$145
- plus $2K from 34 others
What the payments were for
- Food & beverage$2,975100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $249 |
| Biogen | 13 | $219 |
| AstraZeneca | 10 | $190 |
| Sanofi | 10 | $185 |
| Lundbeck LLC | 9 | $185 |
| Sunovion Pharmaceuticals Inc. | 11 | $145 |
| Avanir Pharmaceuticals, Inc. | 8 | $128 |
| Eisai Inc. | 7 | $115 |
| EMD Serono, Inc. | 9 | $113 |
| AbbVie(2 entities) | 8 | $112 |
| Livanova USA, Inc. | 3 | $105 |
| Supernus Pharmaceuticals, Inc. | 5 | $100 |
| Adamas Pharmaceuticals, Inc. | 6 | $97 |
| Catalyst Pharmaceuticals, Inc. | 3 | $95 |
| Amgen(2 entities) | 2 | $94 |
| Teva Pharmaceuticals USA, Inc. | 5 | $79 |
| MDD US Operations, LLC | 4 | $73 |
| Neurocrine Biosciences, Inc. | 4 | $69 |
| SK Life Science, Inc. | 4 | $64 |
| CSL Behring | 3 | $50 |
| Greenwich Biosciences, Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Neurelis, Inc. | 3 | $45 |
| Amneal Pharmaceuticals LLC | 3 | $39 |
| Shire North American Group Inc | 2 | $37 |
| Acadia Pharmaceuticals Inc | 3 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Lilly USA, LLC | 2 | $25 |
| Saol Therapeutics Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Promius Pharma LLC | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
| Pfizer | 1 | $14 |
| Abbott | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Strongbridge US Inc. | 1 | $12 |
| Ceribell, Inc. | 1 | $11 |
How this compares
$2,975 in reported general payments places this provider in the 55th percentile of 474 neurology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 12 | $7,657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $39 | $7,65712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 474 neurology providers in Virginia.
Other neurology in Roanoke
- Aashit ShahRoanoke$102K
- Michelle BetzVirginia Beach$3.3M
- Daniel CohenNorfolk$2.9M
- Heidi CraytonVienna$2.5M
- Ramsey FalconerAlexandria$2.4M
- Robert ShinCharlottesville$2.2M
- Simon FishmanAlexandria$1.6M
- Ingrid Loma MillerNorfolk$1.2M
- Matthew BarrettHenrico$1.1M
- James BickselMc Lean$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.